Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
November 2013, Vol 4, No 9
November 2013, Vol 4, No 9
Gemcitabine Increases Survival for Patients with Resected Pancreatic Cancer
In the Literature
November 2013, Vol 4, No 9
The prognosis for patients with pancreatic cancer is poor, even for patients with surgically resectable tumors. Gemcitabine (Gemzar) is the standard chemotherapy for advanced pancreatic cancer.
Read Article
Denosumab Improves Bone Metastasis–Free Survival in Patients with CRPC
In the Literature
November 2013, Vol 4, No 9
In a new exploratory analysis, researchers evaluated the relationship between PSA doubling time and BMFS, time to first bone metastasis, and OS in recipients of denosumab and placebo (Smith MR, et al.
J Clin Oncol
. 2013;31:3800-3806).
Read Article
Empire Genomics to Launch New CLIA-Approved Tests in 2014 for Myeloma, Prostate Cancer
Value Propositions
,
Value Peer-spectives
November 2013, Vol 4, No 9
Empire Genomics, an emerging molecular diagnostics company focused on cancer diagnostics, has recently received approval from the New York State Department of Health for its diagnostic test facility.
Read Article
Translating Cancer Genetics into Patient Care Focus of New Joint Center for Precision Medicine
Value Propositions
,
Value Peer-spectives
November 2013, Vol 4, No 9
A new collaborative initiative among Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard has been established to create treatment pathways based on precision (or personalized) medicine for patients with advanced cancer and to try to accelerate the development of personalized therapies.
Read Article
1-Dose HPV Vaccine Sufficient to Protect from Cervical Cancer, Save Costs
Value Propositions
,
Value Peer-spectives
November 2013, Vol 4, No 9
A simplified administration schedule of only 1 dose, instead of the current standard of 3 doses, of the human papillomavirus (HPV) vaccine appears to be all women need to be protected from cervical cancer, according to new data from a study funded by the National Cancer Institute (NCI) and recently published (Safaeian M, et al.
Cancer Prev Res [Phila]
. 2013;6:1242-1250).
Read Article
New Technique Selectively Enables Cancer Drugs to Target Malignant Cells while Sparing Healthy Cells
Value Propositions
,
Value Peer-spectives
November 2013, Vol 4, No 9
Researchers led by Nobuhide Ueki, PhD, Assistant Research Professor, Department of Molecular Genetics & Microbiology, Stony Brook University, have found a new way to get targeted cancer drugs to selectively affect only the cancer cells of a patient and not the healthy cells that are also normally affected by the drug (and cause its toxicity), thereby removing many of the potential side effects of the drugs, which would of course greatly enhance the value of cancer drugs.
Read Article
Imbruvica, Second Breakthrough Therapy Drug, Gets FDA Approval for Mantle-Cell Lymphoma
FDA Approvals, News & Updates
November 2013, Vol 4, No 9
A few days after the first drug with a breakthrough therapy designation was approved by the US Food and Drug Administration (FDA), ibrutinib (Imbruvica; Pharmacyclics/Janssen Biotech)—the second drug with such a designation—received an accelerated FDA approval for the treatment of patients with mantle-cell lymphoma (MCL), a rare form of non-Hodgkin lymphoma (NHL). MCL represents approximately 6% of all cases of NHL in the United States.
Read Article
Gazyva, First Breakthrough Therapy to Receive FDA Approval, Indicated for Chronic Lymphocytic Leukemia
FDA Approvals, News & Updates
November 2013, Vol 4, No 9
Using its priority review pathway, the US Food and Drug Administration (FDA) approved the monoclonal antibody obinutuzumab (Gazyva; Genentech) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not previously received treatment for CLL. Obinutuzumab is approved to be used in combination with chlorambucil.
Read Article
Rising Costs of Cancer Survivorship a Growing Concern
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
,
Survivorship
November 2013, Vol 4, No 9
Survival is not cheap. In fact, according to the results of a new study, cancer survivors have ongoing annual medical expenditures averaging $17,000 per patient in the first year after diagnosis, or $6400 per patient at least 1 year postdiagnosis (Guy GP Jr, et al. J Clin Oncol. 2013;31:3749-3757).
Read Article
Bronchial/Nasal Gene-Expression Tests for Early Detection of Lung Cancer
By
Wayne Kuznar
Personalized Medicine
November 2013, Vol 4, No 9
Diagnosing lung cancer by swabbing a patient’s nose may be possible in the not-too-distant future. Changes in nasal gene expression in patients with lung cancer have been found to correlate with changes in gene expression in the bronchus, opening the door to the possibility of nasal gene expression as an early diagnostic biomarker of lung cancer, said Avrum Spira, MD, MSc, Director, Translational Bioinformatics Program, Boston University Clinical and Translational Science Institute.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma